Inhibikase Therapeutics, Inc. (IKT) — Cash & Equivalents
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $178.80M | +83.4% |
| 2024 | $97.50M | +959.8% |
| 2023 | $9.20M | +28.0% |
| 2022 | $7.19M | -82.4% |
| 2021 | $40.75M | — |
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $178.80M | +83.4% |
| 2024 | $97.50M | +959.8% |
| 2023 | $9.20M | +28.0% |
| 2022 | $7.19M | -82.4% |
| 2021 | $40.75M | — |